Year All2026202520242023202220212020201920182017 July 20, 2026 Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform Read More July 14, 2026 Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain Read More June 9, 2026 Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits Read More June 2, 2026 Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026 Read More May 26, 2026 Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium Read More May 20, 2026 Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring Read More May 14, 2026 Personalis to Participate in Upcoming Investor Events Read More May 13, 2026 Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors Read More May 7, 2026 Personalis Reports First Quarter Results and Recent Highlights Read More April 23, 2026 Personalis to Announce First Quarter 2026 Financial Results Read More